bioMerieux SA - Company Profile
Powered by 
All the sales intelligence you need on bioMerieux SA in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how bioMerieux SA fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with bioMerieux SA.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
bioMerieux SA (bioMerieux), a subsidiary of Institut Merieux SA, develops, manufactures, and markets in vitro diagnostic solutions for hospital and private laboratories. The company offers diagnostic solutions such as systems, cardiovascular diseases and cancers, besides identifying microorganisms in pharmaceuticals, cosmetics, reagents and software for the diagnosis of infectious diseases, and agri-food products. It offers immunoassays, microbiology products, molecular biology tests, and other solutions for clinical applications and industrial microbiological control solutions for the food, veterinary diagnostic laboratories; biopharmaceutical, and cosmetic industries; and blood banks. bioMerieux also provides solutions for the enumeration of bacterial flora, which indicate the quality of food products. The company distributes its products directly and through a network of distributors across the world. bioMerieux is headquartered in Marcy l’Etoile, France.
Headquarters
France
Address
376, Chemin De L'Orme, Marcy-l'Etoile, Craponne, Rhone Alpes, 69280
Website
www.biomerieux.com/fr/fr.html
Telephone
33 4 78872000
No of Employees
15,226
Industry
Medical Equipment
Ticker Symbol & Exchange
BIM (EPA)
Revenue (2024)
$4.6B
2.3%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-8.1%
(2024 vs 2023)
Market Cap*
$9.4B
Net Profit Margin (2024)
XYZ
-10.1%
(2024 vs 2023)
* As of and is in US$
bioMerieux SA premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| - | - | Gene UP |
| Microbiology: | Quality Management | Vetfire |
| WASPLab | Lab Organization Services | Vidas |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | New Products/Services | In June, the company launched GENE-UP TYPER SLM, a new real-time PCR solution. |
| 2026 | Corporate Changes/Expansions | In May, the company invested EUR250 million to construct a new manufacturing facility in La Balme-les-Grottes, Isere, France. |
| 2026 | New Products/Services | In April, the company introduced BIOFIRE SPOTFIRE, a molecular testing system for the pharmaceutical industry. |
Competitor Comparison
| Key Parameters | bioMerieux SA | Thermo Fisher Scientific Inc | Abbott Laboratories | Siemens Healthineers AG | Danaher Corp |
|---|---|---|---|---|---|
| Headquarters | France | United States of America | United States of America | Germany | United States of America |
| City | Craponne | Waltham | Abbott Park | Forchheim | Washington |
| State/Province | Rhone Alpes | Massachusetts | Illinois | Bayern | WashingtonD.C. |
| No. of Employees | 15,226 | 125,000 | 115,000 | 72,000 | 58,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Alexandre Merieux | Chairman | Executive Board | 2017 | 51 |
| Pierre Boulud | Chief Executive Officer | Senior Management | 2023 | - |
| Guillaume Bouhours | Chief Financial Officer; Executive Vice President - Purchasing and Information Systems | Senior Management | 2018 | - |
| Charles K. Cooper | Chief Medical Officer; Executive Vice President | Senior Management | 2024 | 66 |
| Celine Roger-Dalbert | Executive Vice President - Research & Development | Senior Management | 2024 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer